Agenus hopes the layoffs and pipeline narrowing will save $40 million that can be redirected to accelerate the lead program’s return to the FDA.
Agenus is putting its CTLA-4/PD-1 combo treatment center stage for the time being, while hauling all other unpartnered programs up to the attic for safekeeping. The strategic prioritization will also see 25% of the biotech’s employees headed out to the curb.
The immuno-oncology company had to pull one half of the combination, balstilimab, from FDA consideration in cervical cancer in 2021. Now the Massachusetts-based biotech is accelerating the PD-1 antibody in combination with the CTLA-4 antibodybotensilimab, nicknamed BOT/BAL. Agenus hopes the layoffs and pipeline narrowing will together save $40 million that can be redirected to accelerate the lead program’s development as it gears up to resubmit to regulators next year.
It means that Agenus is temporarily postponing all preclinical and clinical programs that are not related to BOT/BAL, although partnered programs will continue as planned. The company said that the plan will concentrate quality, manufacturing, clinical, regulatory and R&D resources on the flagship program.
The company was keen to stress that there was a route back for these other programs, claiming that it “remains dedicated to its deep pipeline of immuno-oncology agents and plans to reactivate these programs in the future.”
But balstilimab has always been the star—albeit a troubled one. Agenus filed it for an accelerated approval in cervical cancer in October 2021 only to withdraw the application when the market closed upon the full approval of Merck’s blockbuster Keytruda.
Agenus then pointed to other indications where combining with with botensilimab might have more luck. BOT/BAL is currently being tested in phase 2 trials for colorectal cancer and melanoma, as well as a phase 1 trial for solid tumors, according to the company’s website.
"Now is the pivotal moment to concentrate our efforts on the BOT/BAL program,” CEO Garo Armen, Ph.D., said in today's release. “The observed clinical benefit in solid tumors underscores the program’s game-changing potential and our rapid progress towards a first filing in 2024 highlights the necessity for prioritization in every aspect of our operations."
Editor's Note: Annalee Armstrong contributed to this story. This story was updated at 12:11 p.m. ET on Aug. 23, 2023, to clarify that balstilimab alone was pulled from FDA consideration.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.